NetScientific plc (“NetScientific” or the “Company”) PDS Biotech and Farmacore Announce Updates to Co-Development of Versamune®-Based COVID-19 Vaccine PDS0203 prioritized for clinical development by PDS Biotech and Farmacore after successful meeting with Brazilian Drug Regulatory Agency London, UK – 11 November 2020 – NetScientific plc (AIM: NSCI), the life sciences, technology investment and commercialisation company, announces that its portfolio company PDS Biotechnology Corporation (“PDS”) (Nasdaq: …
No announcement available or all announcement expired.
PDS Biotechnology
PDS Biotech launch Merck Trials
NetScientific plc (“NetScientific” or the “Company”) PDS Biotech Initiates VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Recurrent/Metastatic Head and Neck Cancer in Collaboration with Merck VERSATILE-002 Trial for First Line Treatment of Recurrent/Metastatic Head and Neck Cancer with Combination PDS0101-KEYTRUDA® is Now Open and Recruiting Patients London, UK – 09 November 2020 – NetScientific plc (AIM: NSCI), the life sciences, technology investment and …
PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101
NetScientific plc (“NetScientific” or the “Company”) PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 in Combination with Standard of Care Chemoradiotherapy in Advanced Cervical Cancer London, UK – 26 October 2020 – NetScientific plc (AIM: NSCI), the life sciences and technology investment and commercialisation company, announces that it its portfolio company PDS Biotechnology Corporation (“PDS”) (Nasdaq: PDSB) today announced the Phase 2 clinical trial …
PDS Announces Closing of $19m Offering
NetScientific plc (“NetScientific” or the “Company”) PDS Biotechnology Corporation Announces Closing of Approx. $19 Million Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Shares NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation (“PDS”) (Nasdaq: PDSB) yesterday announced the closing of its previously announced underwritten public offering of 6,900,000 shares of common stock (inclusive …
PDS Announces Pricing of $16.5m Common Stock Offer
NetScientific plc (“NetScientific” or the “Company”) PDS Biotechnology Corporation Announces Pricing of $16.5 Million Public Offering of Common Stock NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation (“PDS”) (Nasdaq: PDSB) yesterday finalised pricing of its previously announced underwritten public offering which consisted of 6,000,000 shares of common stock at a public offering price of $2.75 …
PDS Announces Proposed Offering of Common Stock
NetScientific plc (“NetScientific” or the “Company”) PDS Biotechnology Corporation Announces Proposed Public Offering of Common Stock NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation (“PDS”) (Nasdaq: PDSB) yesterday announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the offering are to …
PDS Biotechnology Announces Preclinical Data for PDS0203
NetScientific plc (“NetScientific” or the “Company”) PDS Biotechnology Announces Preclinical Data for PDS0203, a T-Cell Activating Recombinant Protein Vaccine Against COVID-19 Versamune-CoV-2 (PDS0203) generated high levels of robust, long-lasting CD8 (killer) T-cell responses and potent neutralizing antibody responses within 14 days of vaccination NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation (“PDS”) (Nasdaq: PDSB) today …
PDS collaborator awarded grant for Versamune
NetScientific plc (“NetScientific” or the “Company”) PDS Biotech Collaborator Granted NIAID Award to Accelerate Development of Versamune®-Based Universal Influenza Vaccine London, UK – 14 July 2020 – NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation (“PDS”) (Nasdaq: PDSB) today announced that PDS Biotech collaborator, Professor J. Woodward of the University of Kentucky School of …
PDS & Farmacore Announce Co-Development-PDS0204
NetScientific plc (“NetScientific” or the “Company”) PDS Biotechnology and Farmacore Biotechnology Announce Co-Development of PDS0204 COVID-19 Vaccine London, UK – 18 June 2020 – NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation (“PDS”) (Nasdaq: PDSB) today announced a co-development agreement with Farmacore Biotechnology for Versamune®-CoV-2FC, a Versamune®-based vaccine aimed at preventing COVID-19 infection. Under …
PDS Announces Initiation of Phase 2 Trial PDS0101
NetScientific plc (“NetScientific” or the “Company”) PDS Biotech Announces initiation of Phase 2 Trial of PDS0101 Led by the National Cancer Institute London, UK – 15 June 2020 – NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation (“PDS”) (Nasdaq: PDSB) today announced that the first patient has been dosed in the National Cancer Institute’s …
PDS Announces Trial of its Lead Product, PDS0101
NetScientific plc (“NetScientific” or the “Company”) PDS Biotech Announces Clinical Trial of Its Lead Immunotherapy Product, PDS0101, in Combination with Chemoradiotherapy in Advanced Cervical Cancer London, UK – 5 June 2020 – NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation (“PDS”) (Nasdaq: PDSB) announced yesterday a Phase 2 clinical trial to evaluate its lead …
PDS Reports Results for Q1 2020 & Business Update
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 NetScientific plc (“NetScientific” or the “Company”) PDS Biotechnology Reports Financial Results for the First Quarter 2020 and Provides Business Update London, UK – 13 May 2020 – NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation (“PDS”) (Nasdaq: PDSB) announced …
PDS expands CRADA with National Cancer Institute
NetScientific plc (“NetScientific” or the “Company”) PDS Biotechnology Expands CRADA with the National Cancer Institute to Include Second Versamune®-Based Anti-Cancer Product London, UK – 30 April 2020 – NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, today announces that its portfolio company PDS Biotechnology Corporation (“PDS”) (Nasdaq: PDSB) announced yesterday (29 April 2020) an expansion of its previously announced Cooperative …
PDS Initiates Programs for COVID-19, PDS0101 delay
NetScientific plc (“NetScientific” or the “Company”) PDS Biotechnology Initiates Novel Vaccine Development Programs For COVID-19 and Universal Influenza; Delay of PDS0101 VERSATILE-002 trial London, UK – 16 April 2020 – NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, today announces that its portfolio company PDS Biotechnology Corporation (“PDS”) (Nasdaq: PDSB) announced today an expanded infectious disease pandemic development program, including novel …
PDS Appoints Ilian Iliev to the Board
NetScientific plc (“NetScientific” or the “Company”) PDS Biotechnology Appoints Dr. Ilian Iliev to Board of Directors London, UK – 14 April 2020 – NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, today announces that its portfolio company PDS Biotechnology Corporation (“PDS”) (Nasdaq: PDSB) announced on 9th April 2020 the appointment of Dr. Ilian Iliev to its Board of Directors. Below …
PDS collaborates with Merck in Phase 2 studies
NetScientific plc (“NetScientific” or the “Company”) Portfolio Company PDS Biotechnology collaborates with Merck in Phase 2 studies for PDS0101 in metastatic head and neck cancer and high-risk human papillomavirus-16 (HPV16) infection London, UK – 03 October 2019 – NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, is pleased to note the modification to the collaboration of its portfolio company, PDS Biotechnology …
PDS prioritise PDS0101 in High risk HPV to Phase 2
NetScientific plc (“NetScientific” or the “Company”) Portfolio Company PDS Biotechnology to prioritise lead immunotherapy treatment in high-risk human papillomavirus (HPV) into Phase 2 studies London, UK – 1 October 2019 – NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, is pleased to note today’s announcement by portfolio company, PDS Biotechnology (“PDS”) (Nasdaq: PDSB) to prioritise clinical development of PDS0101 in combination …
PDS – positive data for immunotherapy treatment
NetScientific plc (“NetScientific” or the “Company”) Portfolio Company PDS Biotechnology announces new positive data for lead immunotherapy treatment in high-risk human papillomavirus (HPV) London, UK – 19 September 2019 – NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, is pleased to note the new data announced today by portfolio company, PDS Biotechnology (Nasdaq: PDSB), following a post-hoc follow up of its …
PDS second quarter 2019 financial results
1 August 2019 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 NetScientific plc (“NetScientific” or the “Company”) PDS Biotechnology Corporation Reports Second Quarter 2019 Financial Results NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation (“PDS”) (Nasdaq: PDSB) has released its unaudited financial results for the second …
PDS Biotechnology Corporation liquidity funding program
31 July 2019 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 NetScientific plc (“NetScientific” or the “Company”) PDS Biotechnology Corporation liquidity funding program NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation (“PDS”) (Nasdaq:PDSB) has announced a liquidity funding program with Aspire Capital Fund, LLC (“Aspire”), an Illinois …
PDS Biotechnology Journal Publication
16 May 2019 NetScientific plc (“NetScientific” or the “Company”) PDS Biotechnology journal publication NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation (“PDS”) (Nasdaq:PDSB) has announced a peer-reviewed publication supporting the novel mechanisms of action of PDS’s proprietary Versamune® platform in cancer immunotherapy. The article “Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles …
PDS merger with Edge Therapeutics update
19 March 2019 NetScientific plc (“NetScientific” or the “Company”) PDS merger with Edge Therapeutics update Further to its announcements on 26 November 2018 and 18 March 2019, the Company announces that its ownership of the enlarged PDS Biotechnology Corporation (“PDS”), trading on Nasdaq under the ticker PDSB, on a fully-diluted basis is 8.15%, which at the listing price on 18 March 2019 of …
PDS completes merger with Edge Therapeutics
18 March 2019 NetScientific plc (“NetScientific” or the “Company”) PDS completes merger with Edge Therapeutics Further to its announcement 26 November 2018, NetScientific plc (AIM: NSCI) is pleased to announce that PDS Biotechnology Corporation, a privately-held Portfolio Company which focuses on late clinical-stage cancer immunotherapy company, and Edge Therapeutics, Inc. (Nasdaq: EDGE) have completed their all share merger and that trading of the …
PDS Biotechnology Enters into Merger Agreement with Edge Therapeutics to Form NASDAQ-Listed Clinical-Stage Cancer Immunotherapy Company
Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and late-stage cancer Growing product pipeline utilising Versamune®, a novel, versatile, multi-functional platform Phase 1/2 clinical data on lead product candidate PDS0101 suggests immunotherapeutic anti-cancer activity and favourable safety profile in early stage cervical cancer Combined company plans to initiate multiple Phase 2b/3 clinical trials of PDS0101 in HPV-associated cancers …
NetScientific CEO to Present at Proactive Investors at 18:30 on the 7th December 2017
London, UK – 04 December 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group announces that Francois Martelet, Chief Executive Officer, will be presenting at the Proactive Investors Conference in London at the Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, on Thursday 07 December at 18:30 GMT # # # For more information, please contact: NetScientific François R. Martelet, …
PDS Biotechnology Announces Clinical Collaboration with Merck & Co., Inc.
London, UK – July 10th 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic IP commercialisation group focused on healthcare, announces a new clinical trial collaboration agreement between its portfolio company PDS Biotechnology Corporation (“PDS”) and a subsidiary of Merck & Co., Inc. (known as MSD outside the United States and Canada). The agreement will enable PDS to evaluate the combination of its Versamune®-based PDS0101 …
Executed Warrants
RNS Number : 0278S NetScientific PLC 16 December 2016 (“NetScientific” or the “Company” or the “Group”) NetScientific Executed Warrants in Portfolio Company, PDS Biotechnology, a new paradigm in cancer immunotherapy London, UK – 16 December 2016 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that it has exercised warrants for 1,387,480 shares in its portfolio company, PDS Biotechnology. The total price …
PDS Biotechnology Reports Positive Phase 1 Results
RNS Number : 0007V NetScientific PLC 13 April 2016 NetScientific plc (“NetScientific” or the “Company” or the “Group”) NetScientific Portfolio Company PDS Biotechnology will embark on multiple Phase 2 studies following positive results following the completion of its Phase I study for PDS0101 Immunotherapy for HPV-Related Cancers London, UK – 13/4/2016 – NetScientific plc (AIM: NSCI), the transatlantic healthcare technology group, is pleased …
PDS Biotechnology partners with NCI
RNS Number : 5158O NetScientific PLC 09 February 2016 NetScientific plc PDS Biotechnology partners with National Cancer Institute in Phase II clinical trials for novel cancer immunotherapies London, UK – 9 February 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, is pleased to note that one of its portfolio companies, PDS Biotechnology, has signed …
PDS Biotechnology adds drug development executives
RNS Number : 4379M NetScientific PLC 20 January 2016 NetScientific plc PDS Biotechnology appoints Chief Medical Officer and VP of Drug Development and Manufacturing to drive its clinical programmes London, UK – 20 January 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, notes that its portfolio company, PDS Biotechnology, has appointed Dr. Robert Shepard, …
NetScientific invests in PDS Biotechnology
RNS Number : 7136Z NetScientific PLC 15 December 2014 NetScientific plc (‘NetScientific’ or ‘the Group’) NetScientific Invests in Next Generation, Immunotherapeutics Company, PDS Biotechnology 15 December 2014: NetScientific (AIM:NSCI), the biomedical and healthcare technology group, today announced it has made an investment in PDS Biotechnology Corporation (‘PDS’). PDS is a clinical stage immunotherapy company developing a next-generation of simpler, safer and more …
NetScientific Invests in Breakout Labs Companies
RNS Number : 0808N NetScientific PLC 23 July 2014 23 July 2014 NetScientific invests in a further two Breakout Labs portfolio companies NetScientific plc (AIM:NSCI, ‘NetScientific’ or ‘The Group’), the biomedical and healthcare technology investment group, is pleased to announce it has made a further two investments in portfolio companies from Breakout Labs, Peter Thiel’s revolving philanthropic fund that …
NetScientific plc
Level 39,
One Canada Square,
London, E14 5AB
Tel: +44 20 3514 1800
www.netscientific.net
info@netscientific.net
copyright
PDS Biotechnology Archives - NetScientific